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Summary
Mupirocin, a polyketide-derived antibiotic from Pseu-
domonas fluorescens NCIMB10586, is a mixture of
pseudomonic acids (PA) that target isoleucyl-tRNA
synthase. The mup gene cluster encodes both type
I polyketide synthases and monofunctional enzymes
that should play a role during the conversion of the
product of the polyketide synthase into the active an-
tibiotic (tailoring). By in-frame deletion analysis of se-
lected tailoring open-reading frames we show that
mupQ, mupS, mupT, and mupW are essential for mu-
pirocin production, whereas mupO, mupU, mupV, and
macpE are essential for production of PA-A but not
PA-B. Therefore, PA-B is not simply produced by hy-
droxylation of PA-A but is either a precursor of PA-A
or a shunt product. In the mupW mutant, a new me-
tabolite lacking the tetrahydropyran ring is produced,
implicating mupW in oxidation of the 16-methyl group.
Introduction
A wide variety of compounds of pharmaceutical value
are derived at least in part via polyketide biosynthetic
pathways [1]. One of the most interesting discoveries
in recent years concerns the type I modular polyketide
synthases (PKS) that consist of megaproteins, in which
every addition to the growing polyketide chain is cata-
lyzed by a distinct module, each of which contains a
ketosynthase (KS) domain [2]. In such multifunctional
polypeptides, the chemical structure elaborated by
subsequent selective keto reduction, dehydration, and
enoyl reduction after the condensative addition of an
extender unit can be predicted from the enzymatic*Correspondence: c.m.thomas@bham.ac.uk
3 Present address: Biotica Technology, Ltd., Chesterford Research
Park, Little Chesterford, Nr Saffron Walden, Essex CB10 1XL,
United Kingdom.
4 Present address: Botany Department, Faculty of Sciences (Da-
mietta), University of Mansoura, Damietta El-Gededa, PO Box
35417, Egypt.activities present in each module, via sequence align-
ments, as exemplified first by the erythromycin-biosyn-
thetic cluster [3]. Once the polyketide-synthase-derived
core is produced, it is often further modified by a series
of tailoring steps, which may be changes to the back-
bone or addition of moieties such as sugars. Formation
of hybrid PKS systems to produce novel products has
been extensively reviewed [4–7]. There have been fewer
examples of manipulation of the tailoring genes, but the
recent production of prerapamycin provides a powerful
example [8]. Rational use of this approach depends on
understanding the role of each enzyme in the biosyn-
thetic cluster.
Mupirocin, a polyketide-derived antibiotic produced
by Pseudomonas fluorescens NCIMB10586, inhibits
isoleucyl-tRNA synthase and is used to control infec-
tions by methicillin-resistant Staphylococcus aureus,
MRSA [9]. The mupirocin structure consists of two ele-
ments, monic acid (MA) and 9-hydroxy-nonanoic acid
(1, 9-HN), joined by an ester linkage [10–12] (Figure 1).
Analysis of the fate of isotopically labeled precursors
[13, 14] gave rise to a plausible biosynthetic pathway
for the primary carbon chain of monic acid that fits well
with the biosynthetic enzyme activities predicted from
the DNA sequence of the cluster (Figure 2) [15]. It is
less obvious how 9-HN is made and a number of possi-
bilities have been described previously [15]. As with
many other natural products, mupirocin is a mixture of
more than one compound—termed pseudomonic acids,
of which PA-A to PA-D (compounds 1 to 4) are the most
common (Figure 1). A second group of related second-
ary metabolites isolated from the marine bacterium, Al-
teromonas rava, the thiomarinols, have very similar
structures (compounds 5 to 8) and may be the product
of closely related genes (Figure 3) [16, 17]. Apart from
all lacking the 10,11-epoxide, they show structures that
suggest similar tailoring steps to those involved in
PA-A biosynthesis, and consideration of these may
help to interpret available information about mupirocin.
The different related compounds observed in both
these systems may be intermediates from the pathway
or could be shunt products. However, one of the most
intriguing questions arising from analysis of the mup
cluster is why there are so many tailoring enzymes be-
cause there would appear to be many more than are
necessary for the number of additional modification
steps involved in the biosynthetic pathway.
The work described here is part of a larger study to
determine the role that each of the individual protein-
coding genes in the tailoring region plays in the biosyn-
thesis of mupirocin. It is already clear that the mup
cluster does not follow the simple relationship between
gene order and biosynthetic order exhibited by the
erythromycin and most other modular type I genes [3].
This study focused on the genes closest to the down-
stream end of the cluster, relative to the major direction
of transcription. The region chosen for the subject of
this study was defined at the upstream end by mupM
and mupN, which encode obvious functions (mupir-
ocin-resistant isoleucyl tRNA synthase and phospho-
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826Figure 1. The Structures of the Major Pseu-
domonic Acids
Pseudomonic acid A (PA-A) (compound 1)
forms 90% ; PA-B (compound 2) forms 8%;
PA-C (compound 3) forms <2% ; and PA-D
(compound 4) forms <0.2%.netic analysis followed by identification of intermedi-targeted in this study because establishing which orf if
Figure 2. Summary of the Mupirocin Biosynthetic Gene Cluster
Boxes represent functional domains of polypeptides. Arrows below the boxes represent ORFs, indicating also the direction of transcription.pantetheinyl transferase, respectively), and at the down- a
ostream end by the transcriptional terminator after
mupX. Deletions of mupR and mupS in this region have t
ipreviously been reported to result in complete loss of
antibiotic production [15–18]. The mupP region was not mny is active will involve considerable work—the most
bvious candidate is encoded on the opposite strand
o most other genes in the cluster, but it is not clear
f it will be expressed. Therefore mupO, mupQ, mupT,
upU, mupV, mupW, and mupX were selected for ge-
Tailoring Region of Mupirocin Biosynthetic Cluster
827Figure 3. Thiomarinol-Related Compounds
Structure of thiomarinol metabolites or precur-
sors as determined previously [16, 17–36].ates that might be produced with HPLC, mass spec-
trometry, and then NMR spectroscopy in selected
cases. The results show that the genes encode late bio-
synthetic steps and suggest that multiple genes may
work together to catalyze individual tailoring steps.
Results
All Genes Clustered at the Downstream End
of the mup Region Are Required for Normal
Mupirocin Biosynthesis
In-frame chromosomal deletions were constructed in
each of the selected genes—mupO encoding a putative
cytochrome P450 (339 codons were deleted leaving a
polypeptide of 116 aa), mupQ encoding a putative acyl-
CoA synthase (145 codons were deleted leaving a poly-
peptide of 307 aa), mupT encoding a putative ferre-
doxin dioxygenase (58 codons were deleted leaving a
polypeptide of 59 aa), mupU encoding a second puta-
tive acyl-CoA synthase (501 codons were deleted leav-
ing a polypeptide of 24 aa), mupV encoding a putative
oxidoreductase (596 codons were deleted leaving a
polypeptide of 67 aa), mupW encoding a putative di-
oxygenase (350 codons were deleted leaving a poly-
peptide of 114 aa), and mupX encoding a putative ami-
dase or hydrolase (415 codons were deleted leaving a
polypeptide of 98 aa). As part of a separate study of
the acyl carier proteins (to be published fully elsewhere)
macpE was also inactivated in a similar manner, delet-
ing 71 codons to leave a polypeptide of just 6 aa from
the start and 3 aa from the end of the protein. It is in-
cluded here because of the phenotype it generates as
described below. In-frame deletions were made to mini-
mize polar effects so that the resulting phenotype
should be the result of specifically knocking out the tar-
get gene (or genes) and not because of the decreased
expression of downstream, nontarget genes. The spe-
cific deletions in the target genes were created be-
tween two flanking arms, each at least 500 bp in length
as described in Experimental Procedures.
A suicide vector system, pAKE604, was used to in-sert these deletions into the chromosome as described
in Experimental Procedures [15]. Antibiotic production
by the mutants was evaluated with the plate bioassay
(see Experimental Procedures), which assessed the
ability of the experimental strains to produce mupir-
ocin, indicated by the average area in cm2 of their zone
of inhibition relative to the size of wild-type zone. The
wild-type strain gave an average area of 10.1 cm2, and
a mutant strain, AKE3 (mupI) [18], used as a “nonpro-
ducer” control, gave an average halo area of 1.8 cm2.
Each mutant demonstrated reduced antibiotic activity
to varying extents (Figure 4) with mupQ and mupT
effectively indistinguishable from mupI. The mutant
bioassay phenotypes split into two groups. The first
group, containing mutants mupQ, mupT, mupW,
and mupX, showed a smaller but clear halo. The sec-
ond group, containing mupO, mupU, and mupV,
gave a halo with two distinct regions—a central clear
zone surrounded by a more diffuse zone. The macpE
mutant gave a plate assay phenotype indistinguishable
from this second group (data not shown).
Although the mutations were designed not to disrupt
transcription or translation of the remainder of the tar-
get genes, it is possible that the deletions also reduced
the expression of downstream genes (a “polar effect”)
in the mup operon, giving a false phenotype. Therefore,
it was necessary to determine whether the mutations
could be complemented in trans. All genes of interest
were cloned separately into an IncQ-based expression
vector (pJH10) as described in Experimental Proce-
dures. Plasmid pJH10 contains a tac promoter, an oriT
region, a multiple cloning site, and a tetracycline resis-
tance gene. The results of these complementation
studies were evaluated with the plate bioassay (see Ex-
perimental Procedures) on agar with and without IPTG.
Inhibition zone sizes were compared with the equiva-
lent strains carrying just the expression vector. Antibi-
otic production was restored in all the mutants by their
respective genes cloned in trans, indicating that the de-
letions did not have secondary effects. The strains
mupQ, mupW, and mupX exhibited better comple-
mentation (i.e., bigger zones of inhibition) in the ab-
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notypes Observed
With wild-type taken as 100%, the relative
size of the zone of inhibition is indicated.
The mutants are grouped by phenotype—
mupO, mupU, and mupV give a diffuse
edge, whereas mupQ, mupT, mupW, and
mupX give a clear/distinct edge. The data
is the mean of three measurements. Stan-
dard deviations were of the order of 6% to
10% so that the large differences are signifi-
cant, whereas the small ones are not.sence of IPTG, suggesting that low levels of expression
(possibly from inefficient translation because it is likely
that most if not all the genes are in the same transcrip-
tional unit) (J.H. and C.M.T., unpublished data) are opti-
mal for gene function. However, for mupO, mupT,
and mupV, complementation was better in the pres-
ence of IPTG, indicating that a higher level of gene ex-
pression is optimal. In the absence of IPTG, macpE in
trans restored mupirocin production to wt levels (100%),
whereas in the presence of 0.1 mM and 0.5 mM IPTG,
the zones of inhibition were slightly reduced (85%)
when compared to wt.
Because sequence alignments suggest that both
MupQ and MupU may have acyl-CoA ligase activities,
it was possible that they might be able to substitute for
each other. Because knocking out each one individually
resulted in different but significant defects in antibiotic
production, there clearly is not complete functional re-
dundancy between them. Nevertheless, we created a
double mutant to check whether this gave a more se-
vere defect compared to either knock out alone. The
phenotype of the mupQU double mutant in the plate
bioassay is indistinguishable from that of the single
mupQ mutation that gives the more severe of the two
mutant phenotypes, suggesting that they do not pro-
vide alternative ways of achieving the same step. This
was confirmed by overproducing mupU in trans to
mupQ and overproducing mupQ in trans to mupU,
which showed no evidence for any cross complemen-
tation between these two genes.
HPLC Analysis of the Products of the WT
and Mutant Strains
The HPLC profile of the supernatant from stationary
phase cultures of wt NCIMB10586 strain under the con-
ditions described in Experimental Procedures and with
detection at 233 nm (Figure 5) revealed one major peak
F
(peak 1) whose retention time was 20.5 min, identified
by comparison with standard as PA-A 1 (Figure 1), and
another smaller peak with retention time 19.6 min (peak nigure 5. Typical HPLC Traces of the Compounds Detectable at 233
m Produced by Wild-Type and Mutant Strains
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8292—PA-B, 2 in Figure 1). A very small peak was also
detected at the same position as peak 2 in the profile
from the negative control, AKE3(mupI), which is de-
fective in expression of the mupirocin biosynthetic
pathway [18]. It is likely that some other material also
elutes at this position.
Analysis of PA-A peak area by HPLC was carried out
for samples taken at different times during growth in
mupirocin production medium (MPM) at 22°C after 20-
fold dilution of the overnight culture. Mupirocin produc-
tion had already begun when sampling commenced at
8 hr, but between 8 and 13 hr, a rapid increase in pseu-
domonic acid production was observed. Maximum an-
tibiotic production (w0.8 g/ml) was reached at ap-
proximately 15 hr, and from this point, levels of PA-A
remained relatively constant. The negative control pro-
duced only a negligible amount of PA-A throughout the
experiment. Therefore, the supernatants of mutant cul-
tures were analyzed at 30 hr. HPLC traces from the
broth of the mupX strain showed a similar profile to
wt but with a smaller area under peak 1 (approximately
85% relative to wt peak 1).
The HPLC traces from the broths of mupO, mupU,
and mupV strains all showed the same profile in which
peak 1 was absent and peak 2 at 19.55 min was now a
similar size to peak 1 in supernatants from wt (70%,
78%, and 122%, respectively, relative to wt peak 1). The
macpE mutant showed the same profile as these mu-
tants with peak 2 being approximately 60% relative to
the size of wt peak 1. Based on area of zones of inhibi-
tion, the macpE mutant exhibits 64% antibacterial ac-
tivity when compared to wt. mupT and mupW broths
typically showed similar peak profiles to each other,
with only small amounts of detectable material (22%
and 17%, respectively, relative to wt). Two peaks were
detected that elute slightly later than peaks 1 and 2
(retention time 20.59 min and 19.61 min, respectively).
Finally, mupQ, mupQU, and mupS (whose plate
bioassay phenotype was reported previously [15]) typi-
cally showed less than 10% the level of detectable
material relative to wt, and this was concentrated at the
position of peak 2. Additional peaks detected at 233
nm with faster or slower elution were sometimes ob-
served for these mutant strains and will eventually be
analyzed in detail. However, in this study, we concen-
trated on the most obvious peaks.
Mass Spectrometric and NMR Analysis
of the Products of Selected Mutants
The calculated relative molecular mass (Mr) of PA-A is
500. The mass spectra of the PA-A standard and PA-A
purified from the wt broth show very similar profiles.
The major peak in both has an Mr of 523, which corres-
ponds to the sodium adduct of PA-A (500 + 23). The
spectra of the purified compound from peak 2 pro-
duced by mupO, mupU, mupV, and macpE
showed a major peak with an Mr of 517, corresponding
to the hydrogen adduct of PA-A plus an oxygen atom
[16]. NMR spectral analysis of this material confirmed
the structure as PA-B when compared with values from
the literature [12]. The major product of mupX (peak
1) was confirmed as PA-A by mass spectrometry and
NMR.Analysis of the product (or products) of mupT and
mupW was more complicated because the total
amount of material that accumulated was considerably
less than in the mutants described in the previous para-
graph. Apart from a small signal corresponding to peak
2, these two mutants showed a new peak at a retention
time about 0.5 min slower than PA-A, close to but not
identical to peak 1. MS and NMR analysis of the com-
pound isolated from mupW showed that this product
(PA-W) did not correspond to any of the previously de-
fined PAs but possesses a novel PA structure 10 (Figure
6), which lacks the characteristic tetrahydropyran ring
common to all known pseudomonic acids. Detailed
structural analysis is described fully elsewhere [19].
Discussion
The genes mupO, mupQ, mupS, mupT, mupU, mupV,
mupW, and mupX were all proposed to be required for
tailoring the core structure produced by the type I PKS
assembly line. Combined with the data presented pre-
viously [15], the results in this paper confirm that in-
deed all mutations studied do affect mupirocin produc-
tion. The effect of the deletion in mupX is the weakest,
simply resulting in an approximately 15% decrease in
production of PA-A. It therefore appears that MupX is
not essential for any step in the biosynthesis but some-
how modifies either the expression of the genes or the
efficiency with which enzymes of the pathway proceed.
The blast hits and sequence alignments suggest that
MupX may have amidase/hydrolase activity. It is pos-
sible that MupX represents a relic of an activity that is
no longer required but remains because the protein is
still a structural component of a multienzyme assembly
essential for mupirocin production. In this regard, it may
be significant that the thiomarinols have an amide de-
rivative at C-1# (Figure 2). One can suggest, therefore,
that MupX may have had a role in removing an amide
derivative.
An important part of our analysis was to demonstrate
that each of the mutants could be complemented,
showing that the phenotype of the mutation was not
because of polar effects. All of the mutants could be
complemented, but the level of induction of the tac pro-
moter by addition of IPTG that was optimal for comple-
mentation varied. It is well known that the tac promoter
control is leaky, so it is to be expected that there will
be a basal level of expression of all the cloned genes
in the absence of IPTG. Whether or not addition of IPTG
is necessary may reflect differences in the efficiency of
expression of the cloned genes or may indicate the
levels of proteins normally needed for PA production as
well as differences in the consequences of overproduc-
tion. Complemented strains in which antibiotic levels
are reduced in the presence of IPTG might be express-
ing proteins that are either toxic to the cell or inhibit the
synthesis of mupirocin when expressed at high levels.
Mutation of mupW results in the formation of a new
metabolite, which we have shown to have the structure
10 (Figure 5) lacking the characteristic tetrahydropyran
ring found in the pseudomonic acids and thiomarinols
[19]. One possibility is that pseudomonic acid W (10) is
formed from an acyclic biosynthetic intermediate, e.g.,
Chemistry & Biology
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Structure of the intermediate PA-W that accumulates in the mupW mutant (10) [19] and proposed action of MupW on the hypothetical
intermediate (9) to form the pyran ring. PA-W otherwise spontaneously converts to compound 10.9, by opening of a 10,11-epoxide at C-10 by 7-OH (Fig- t
Mure 5). That mupW is the gene responsible for 16-
hydroxylation would be consistent with its predicted T
abiochemical activity. Mutation of mupW blocks hydroxyl-
ation, but the other proposed late-stage modifications, p
f5-hydroxylation, 10,11-epoxidation, and esterification
with 9-HN still take place. This implies that it is not m
Messential for MA synthesis to be completed before es-
terification with 9-HN. MupT may also be involved in
Mthis step but has not yet been characterized in more
detail. m
fOf the remaining mutations that generate pheno-
types, the most obvious is that exhibited by mupO, o
cmupU, mupV, and macpE, which knock out pro-
duction of PA-A and shift the pathway into producing H
pan equivalent or greater amount of PA-B (80%, 87%,
137%, and 60% relative to wt, respectively). This could P
dsuggest that the protein products of these genes are
all involved in the same biosynthetic step. MupO is a [
aputative P450 monooxygenase. P450s commonly cata-
lyze reactions involving oxygen transfer, which are typi- s
ocal in post-PKS tailoring. Cytochrome P450 monooxy-
genases are often found in PKS gene clusters, and P
vthere are many cases of their inactivation leading to a
structure related to the native antibiotic but lacking a 7
mhydroxyl or epoxide group. For example, the disruption
of pimD, a gene encoding a P450 monoxygenase in the d
rpimaricin gene cluster (S. natalensis), results in the for-
mation of 4,5-deepoxypimaricin [20]. In erythromycin P
wbiosynthesis, inactivation of eryF leads to the accumu-
lation of a derivative lacking the hydroxyl group at C-6 (
d(6-deoxyerythromycin A) [21]. Some atypical reactions
performed by P450s have been reported, however, in- d
ocluding reductions, dehydrations, dehydrogenations, and
isomerizations [22]. Another common feature of P450s b
mis that they function as a part of multicomponent sys-
tems, requiring electron transport proteins to shuttle elec- h
vtrons from NAD(P)H [23]. Such a role could be provided
by MupV, which is predicted to possess NADPH- f
adependent reductase activity. MupU is a putative acyl-
CoA ligase, the obvious role for which would be activa- sion of an intermediate, prior to the action of MupO and
upV, via an acyl adenylate and independently of CoA.
his reaction is similar in rapamycin initiation, occurring
t the loading domain of RAPS1 [24]. It can be pro-
osed, therefore, that the biosynthetic step being af-
ected by these mutations is initiated by MupU loading
AcpE with an intermediate, which is then modified by
upO, supported by MupV (Figure 7).
Where in the biosynthetic scheme might this mAcpE-
upU-O-V complex work? According to the predicted
upirocin biosynthetic pathway [15], PA-A would result
rom epoxidation of PA-C 3 (Figure 1). PA-B would then
riginate from a simple hydroxylation of PA-A at C8, a
ommonly observed process in secondary metabolism.
owever, the accumulation of PA-B at the cost of PA-A
roduction in the mutants reported here indicates that
A-B can not be derived as previously proposed. In-
eed, radio-labeling studies conducted by Mantle et al.
25] were also inconsistent with the model that PA-B
rises from the oxidation of PA-A. Although it is pos-
ible that PA-A may be derived by direct deoxygenation
f PA-B, the observed efficient switching from PA-A to
A-B production can perhaps be best explained by di-
ersion of intermediate flux at a key branchpoint (Figure
). The polyketide precursor 11 predicted from the do-
ain structure of the mupirocin PKS retains an olefinic
ouble bond between carbons 8 and 9. This must be
educed to attain the correct overall oxidation level of
A-A. In a fully processive pathway, this reduction
ould be predicted to occur via an enoyl reductase
ER) at the tetraketide stage, but the appropriate con-
ensation module 3 lacks an ER domain [15]. The re-
uction must therefore be carried out by a reductase
utside the PKS, and a number of candidate genes can
e identified in the mup cluster, e.g., mupC, mupE, and
upV. The timing of this essential reduction step is,
owever, not apparent. It is relevant to this that the lo-
astatin nonaketide synthase encoded by lovA lacks a
unctioning ER domain, and this activity is supplied by
separate gene, lovC. Expression of lovA in the ab-
ence of lovC results in accumulation of nonreduced
Tailoring Region of Mupirocin Biosynthetic Cluster
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Branchpoint in the Biosynthetic Pathway
In branch one, the MupO-U-V-mACPE com-
plex catalyzes the reduction of the C8-C9 al-
kene bond so that the subsequent action of
MupW produces a hydroxyl at C16, which
then cyclizes to produce the pyran ring. In
the absence of the reduction step, isomer-
ization leads to a C8-C16 alkene that pro-
duces an epoxide ring with the action of
MupW, eventually leading to the PA-B struc-
ture as shown.shunt products [26]. We would thus suggest that the
putative MupO-MupU-MupV-mAcpE complex is in-
volved in this key reduction step and so controls the
flux of intermediates down this channel. Although there
are a number of possibilities, the timing of its interven-
tion would likely be at the end of PKS assembly, or con-
ceivably after addition of 9-HN. Subsequent post-PKS
tailoring steps including MupW-initiated cyclisation
(Figure 7) would lead to PA-A. Disruption of the full
functionality of this complex by any of the reported mu-
tations would lead to PA-B. At this stage, we can only
speculate on the mechanism and the genes involved,
but an interesting possible mechanism would be isom-
erization of the 8,9-olefin 11 to give the 8,16-isomer 13.
Subsequent epoxidation to 14, perhaps also catalyzed
by MupW, would allow an alternative mechanism of
tetrahydropyran-ring closure, which would form the
tetrahydropyran ring and introduce the 8-hydroxyl in
one step as shown. The resulting intermediate 15 would
require efficient conversion by the remaining tailoring
enzymes to produce PA-B in comparable yields to
those of PA-A observed in the wt strain. A much-
reduced flux of intermediate 11 through this channel
would produce the small amounts of PA-B observed in
wt and would be consistent with this mechanism. The
formation of TM-G 8, which lacks the extra 4- and
6-hydroxylations, could be circumstantial evidence for
the timing of the cyclization. Presumably in this case,
intermediate 15, or TM-G itself, is a less suitable sub-
strate for the tailoring enzymes in Alteromonas rava
than its counterpart in Pseudomonas fluorescens. This
hypothesis is testable by isolation and characterization
of mACP16 attached to its biosynthetic intermediate,
which is a current aim of this laboratory. It is also pos-
sible that MupO, MupU, MupV, and mACP16 form a
complex that could be isolated by affinity tagging any
one of the component proteins. Finally, it is worth not-
ing that the apparent involvement of multiple tailoring
genes in a single biosynthetic step may provide a par-
tial answer to why there are so many tailoring genes.
Further study of the rest of this region should provide
the rest of the explanation.Significance
The mupirocin biosynthetic cluster has a number of
unusual features that distinguish it from many pre-
viously studied polyketide biosynthetic pathways. It
may thus provide an alternative model system appli-
cable to other natural products such as the thiomari-
nols. The role of the tailoring genes is the least pre-
dictable part of the scheme. This analysis of a
selected group of mup genes is of great significance
in linking genes to biosynthetic function and has
prompted us to propose a testable hypothesis for key
steps leading to the formation of the central pyran
ring in monic acid. This provides an explanation for
the synthesis of the two major pseudomonic acids, A
and B. Although in this paper we have focused on
the mutations that cause the most identifiable shift in
biosynthesis, we also report that the mupW mutant,
which accumulates much less intermediate, is never-
theless informative. A challenge for the future is to
determine whether there are minor peaks in other mu-
tants that can also be informative.
Experimental Procedures
Bacterial Strains, Plasmids, and Growth Conditions
The wild-type mupirocin-producing bacterium used in this study
was P. fluorescens NCIMB 10586 [27]. Escherichia coli DH5α was
used for plasmid propagation and as the recipient of constructed
plasmids in all transformations [28]. The strain E. coli S17-1 was
used for mobilizing recombinant plasmids into P. fluorescens [29].
Bacillus subtilis 1604 was used for the determination of mupirocin
production by bioassay. Previously described plasmids used were
as follows: pGEM-T Easy (Promega); pAKE604 [18]; and pAKE800,
pAKE5.8X, pAKE5.8H, and pJH10 [15]. All bacterial strains were
routinely grown in LB medium or on L-agar plates [30], except for
mupirocin-production-medium (MPM) [27] used when antibiotic
biosynthesis was specifically being studied. P. fluorescens strains
were grown in two stages. For seed cultures, a single colony was
used to inoculate 25 ml of primary medium in a 250 ml conical flask
and incubated at 25°C, 200 rpm for 24 hr. For mupirocin-produc-
tion-culture stage, an aliquot of the seed culture was diluted 20-
fold into MPM and incubated at 22°C, with shaking at 200 rpm for
45–65 hr. Antibiotics were added to medium as required: penicillin
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832(Pn) (150 g/ml in liquid and 300 g/ml in solid medium), ampicillin v
(Ap) (50 g/ml); kanamycin (Km) (50 g/ml); tetracycline (Tc) (25g/ 
ml); and mupirocin (Mup) (500 g/ml). a
p
DNA Isolation and Manipulation
Plasmid DNA was isolated by the alkaline/SDS lysis method [31].
CFor higher quality plasmid DNA extraction, the Wizard plus SV mini-
oprep purification system manufactured by Promega was used in
Taccordance with the manufacturer’s guidelines. A yeast DNA mini-
pprep kit manufactured by Nucleon Tepnel Life Sciences was used
to isolate high quality chromosomal DNA. Restriction enzymes m
were purchased from Gibco BRL, MBI-Fermentas, and New En- d
gland Biolabs (NEB) and used according to the manufacturer’s e
guidelines. Digested DNA was analyzed by agarose gel electropho- E
resis in 1× TAE by standard procedures [32]. DNA fragments were s
purified with the “Geneclean kit” from Bio101. T4 DNA ligase pur- i
chased from Gibco BRL was used for ligations and was incubated p
at 4°C overnight. The ligation reaction was then transformed into T
E. coli DH5α. m
PCR reactions were performed as described by Mullis et al. [33]. t
Template DNA was generated by the standard boiled colony w
method. Primers were designed to flank the region of interest with
extra restriction sites for cloning if needed. Primers were synthe-
sized by Alta Bioscience, University of Birmingham. Table S1, avail- D
able with this article online, lists all primers designed and used in T
this study. The DNA polymerases used were Expand High Fidelity p
system, manufactured by Boehringer Mannheim, for gene cloning t
and Taq polymerase for confirmation of chromosomal genotype. t
Glycerol was added to the diagnostic PCR reactions to a final con- u
centration of 5%. PCR product purification was achieved with a d
HIGH pure purification kit manufactured by Roche. Standard PCR
conditions were as follows: denaturation at 94°C for 4 min; 10 cy-
cles of denaturation at 94°C for 30 s, annealing at 59°C for 30 s, P
annealing at 57°C for 15 s, extension at 72°C for 1.2 min; 20 cycles B
of denaturation at 94°C for 30 s, annealing at 59°C for 30 s, anneal- b
ing at 57°C for 15 s, and extension at 72°C for 1.2 min with an
a
increment of 5 s every cycle; final extension at 72°C for 7 min.
e
w
Automated DNA Sequencing s
DNA sequencing was carried out with Big dye terminating kit man- m
ufactured by PE-ABI and was based on the chain termination
t
method [34]. The sequencing PCR-cycling program involved 25 cy-
4
cles of denaturation at 96°C for 30 s, annealing at 50°C for 15 s
w
and extension at 60°C for 4 min. The ramping time was set to 1°/s.
(The sequence reactions were run on an ABI 3700 DNA sequencer
t(Functional Genomics Laboratory, University of Birmingham).
u
cDNA Transfer
S
Standard methods were used to make E. coli strains competent for
transformation [35]. Cells were stored at −80°C in 100 mM calcium
chloride and 20% glycerol. For mobilization into P. fluorescens, the
donor strain (E. coli S17-1, with appropriate plasmids) was mixed
Swith recipient bacteria on L-agar, incubated at 30°C for 24–30 hr
Sand then spread on solid media containing mupirocin or ampicillin
a(to kill the donor) and appropriate antibiotic to select for the mobi-
8lized plasmid. The transconjugant colonies always grew slowly, re-
quiring incubation at 30°C for up to 72 hr.
ASuicide Mutagenesis for Isolation of Chromosomal Mutations
Specific mutations were introduced into the chromosome as pre-
Sviously described [15]. Construction of in-frame deletions was car-
Bried out as illustrated with respect to mupQ and mupO. For mupQ,
sa 1446 bp fragment was amplified by PCR with primers pmupQ-F
wand pmupQ-R, designed to give flanking EcoRI and XbaI sites, and
Bcloned into pGEMT-Easy. After cloning, the internal 435 bp BstEII
wfragment was deleted by standard procedures, leaving the two
bhalves of the orf in frame and flanking arms of 512 bp and 492 bp.
7The deletion fragment was then cloned into pAKE604. The suicide
mvector was designated pSCQ. For mupO, two PCR fragments
gwere amplified, yielding a 601 bp EcoRI-BamHI product (primers
bpmupO1-F and -R) and a 467 bp BamHI-XbaI product (primers
(pmupO2-F and -R) effectively making a deletion of 1197 bp in
mupO when these were ligated together in pAKE604. The suicide pector was designated pSCO. The mutants mupT, mupV,
mupW, and mupX were also constructed with the same cloning
nd integration strategy used to generate 10586mupO but with
rimers as listed in Table S1, with the nomenclature as for mupO.
onstruction of Expression Plasmids and Complementation
f Deletion Mutants
he ORFs for each of the genes studied were amplified with the
rimers listed in Table S1. These primers placed an EcoRI site im-
ediately upstream of the start codon and a SacI site immediately
ownstream of the stop codon. After initial cloning into pGEMT-
asy vector, the amplified DNA was checked by sequencing. The
coRI-SacI fragment was then ligated between the EcoRI and SacI
ites of the TcR vector pJH10 [15], placing it downstream of the
nducible tac promoter. Each recombinant plasmid was designated
SCC followed by the letter corresponding to the gene involved.
he expression plasmids were introduced into their corresponding
utant host by biparental mating followed by appropriate selec-
ion. As a control the vector, pJH10, with no inserted mup gene,
as always introduced in parallel.
etermination of Mupirocin Activity and Related Compounds
he plate test for antibacterial activity was performed as described
reviously [15]. For HPLC quantitative determination of the concen-
rations of pseudomonic acid and its intermediates from liquid cul-
ures, a calibration curve based on purified mupirocin standard was
sed. Where a standard did not exist, purified intermediates were
ried and weighed.
urification and Structural Analysis of PA Derivatives
acterial liquid cultures were grown in MPM to stationary phase,
acteria removed by centrifugation before acidification to pH 4.5,
nd then solvent was extracted to exhaustion (three times) with
thyl acetate. After evaporation of the ethyl acetate, the residues
ere redissolved in methanol and then separated by HPLC in a
tandard water/acetonitrile gradient (5%–70% acetonitrile over 30
in). HPLC was performed on a Gilson 712 system with UV detec-
or and a reverse phase C18 Supelco Discovery Column (15 cm ×
.6 mm). Alternatively 1 ml samples of 5-fold diluted crude extracts
ere repeatedly injected and separated with an isocratic gradient
32% acetonitrile, 68% water acidified with 0.01% formic acid), and
he appropriate fraction was pooled, dried down and weighed, and
sed for MS (Kratos Profile Mass Spectrometer, School of Chemi-
al Sciences, University of Birmingham) and NMR (JEOL300,
chool of Chemistry, University of Bristol).
upplemental Data
upplemental Data include one table and can be found with this
rticle online at http://www.chembiol.com/cgi/content/full/12/7/
25/DC1/.
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